Drug Sponsors

California Life Sciences Association launches, following BayBio, California Healthcare Institute merger

Friday, May 15, 2015 02:18 PM

The California Life Sciences Association (CLSA) has officially launched as a representation for California’s life sciences sector. CLSA now is the largest state and regional life sciences advocacy group in the country, with more than 750 members. The organization advances California’s life sciences innovation ecosystem by advocating for effective national, state and local public policies and supporting entrepreneurs and life sciences businesses. CLSA is the result of a completed merger between BayBio and California Healthcare Institute.

More... »


Pfizer acquires minority interest in AM-Pharma; secures option to acquire company

Wednesday, May 13, 2015 12:15 PM

Pfizer has acquired a minority equity interest in AM-Pharma, a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, and secured an exclusive option to acquire the remaining equity in the company.

More... »


Juno Therapeutics acquires Stage Cell Therapeutics

Wednesday, May 13, 2015 12:11 PM

Juno Therapeutics, a Seattle, Wash.-based biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, has acquired Stage Cell Therapeutics, a privately held biotechnology company based in Munich and Göttingen, Germany.

More... »

Moderna launches venture company Elpidera for rare diseases

Wednesday, May 13, 2015 11:57 AM

Moderna Therapeutics, a Cambridge, Mass.-based developer of messenger RNA (mRNA) Therapeutics, has launched Elpidera, a new Moderna venture focused exclusively on the advancement of mRNA-based medicines for the treatment of rare diseases.

More... »

Perrigo acquires Patheon's Mexican operations for $34 million in cash

Wednesday, May 13, 2015 11:54 AM

Perrigo, a consumer goods and pharmaceutical company headquartered in Ireland, has acquired the Mexican operations of Durham, N.C.-based Patheon for $34 million in cash.  The acquisition is expected to be immediately accretive to calendar 2015 adjusted EPS after the exclusion of estimates for intangible amortization and transaction-related costs.

More... »

Baxter BioScience acquires Oncaspar portfolio for leukemia

Wednesday, May 13, 2015 11:51 AM

Baxter International has signed a definitive agreement to acquire the Oncaspar (pegaspargase) product portfolio from Sigma-Tau Finanziaria. Baxter gains the marketed biologic treatment Oncaspar, the investigational biologic calaspargase pegol and an established oncology infrastructure with clinical and sales resources.

More... »

Alexion Pharmaceuticals expands in Dublin, to add 200 jobs

Monday, May 11, 2015 03:19 PM

Alexion Pharmaceuticals will significantly expand its operations in Ireland by constructing the company's first ever biologics manufacturing facility outside the U.S. This $502.6 million, four-year project, which will be constructed at Alexion's College Park site in Blanchardstown, is expected to create approximately 200 additional full-time jobs on completion, bringing Alexion's total workforce in Ireland to almost 500.

More... »

UNC-Chapel Hill, GSK partner for HIV cure, launch Qura Therapeutics

Monday, May 11, 2015 02:06 PM

The University of North Carolina at Chapel Hill, a global public research university with experience in HIV basic and clinical research, and GlaxoSmithKline have created the dedicated HIV Cure Center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. This unique public-private partnership will redefine the traditional way of conducting research and create a new model to seek the breakthroughs needed to tackle a global health issue.

More... »

Plasmatech Biopharmaceuticals to acquire Abeona Therapeutics

Friday, May 8, 2015 12:24 PM

PlasmaTech Biopharmaceuticals, a Texas-based biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, has entered into a definitive agreement to acquire Abeona Therapeutics, a company engaged in the development and commercialization of therapies for patients with lysosomal storage diseases. The company will issue to Abeona Therapeutic members a total of 3,979,761 common shares upon closing of the transaction, and up to an additional $9 million in performance milestones, in common stock or cash, at the company’s option.

More... »

Gilead Sciences acquires EpiTherapeutics

Thursday, May 7, 2015 12:24 PM

Gilead Sciences, headquartered in Foster City, Calif., has acquired EpiTherapeutics, a privately held Danish company, for $65 million, subject to certain purchase price adjustments, to be financed through available cash on hand.

More... »

CenterWatch
CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs